UT Southwestern researchers reveal how CDK4/6-inhibitors alter pancreatic cancer cell
UT Southwestern Medical Center researchers have found that cancer drugs known as CDK4/6-inhibitors alter the metabolism of pancreatic cancer cells, revealing a biologic vulnerability that could be exploited for therapeutic gain.